Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Linker-based design connecting antimicrobial peptides and glycans against Infection and Tumours

Project description

Peptides for targeted treatment of cancer and infection

In antimicrobial resistance and cancer the ability of cell membranes to resist drug penetration contributes to treatment failure. Antimicrobial peptides show potent activity against resistant bacteria and cancer cells but lack the selectivity needed for safe clinical use. With the support of the Marie Skłodowska-Curie Actions programme, the Link-IT project will work on a novel strategy that links antimicrobial peptides to targeting sugar molecules through tunable chemical linkers. This approach will guide peptides specifically to cancer or infected cells while sparing healthy tissue. Researchers will combine computational modelling, chemical synthesis and biological testing to establish design rules for selective antimicrobial peptide conjugates. The generated versatile platform will pave the way for next-generation targeted therapeutics against both infection and cancer.

Objective

Antimicrobial resistance and cancer are two of the most urgent health challenges. In both cases, the impermeability and adaptability of cellular membranes contribute to poor drug uptake and favour drug resistance. Antimicrobial peptides (AMPs) are molecules that can efficiently disrupt these resistant membranes, but their lack of specificity often causes toxicity to healthy host cells, limiting their clinical application. This project, Link-IT, will develop a new molecular strategy in which AMPs are connected to targeting glycans through tuneable linkers. The systematic study of linkers connecting highly selective glycans and AMPs to enhance performance has not been investigated previously. This design aims to preserve the intrinsic membrane activity of AMPs while introducing receptor-guided specificity, thereby improving potency and selectivity. This project integrates three complementary work packages: (i) computational modelling to select AMP–linker–glycan constructs based on their stability and interactions with target receptors; (ii) chemical synthesis to generate selected candidates using peptide, glycan and linker chemistry; and (iii) biological testing in bacterial and cancer cell models to evaluate membrane disruption, receptor-mediated uptake and selectivity against healthy cells. Iterative feedback between these steps will establish structure–activity relationships. Expected outcomes will include new insights into how linker properties influence molecular recognition at membranes and the development of selective AMP–glycan conjugates with reduced toxicity. Beyond these immediate applications, Link-IT will provide a versatile platform for the design of future dual-targeting therapeutics.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

UNIVERSIDAD DE SANTIAGO DE COMPOSTELA
Net EU contribution
€ 209 914,56
Address
COLEXIO DE SAN XEROME PRAZA DO OBRADOIRO S/N
15782 Santiago De Compostela
Spain
Region
Noroeste Galicia A Coruña
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data